Discovery of a 9-mer Cationic Peptide (LTX-315) as a Potential First in Class Oncolytic Peptide

Journal of Medicinal Chemistry

Volumn 59, Issue 7, 2016, Pages 2918-2927

  Haug, Bengt Erik ^a,b   Camilio, Ketil André ^a,c   Eliassen, Liv Tone ^a,c   Stensen, Wenche ^a,c   Svendsen, John Sigurd ^a,c   Berg, Kristel ^a,c   Mortensen, Bjarte ^a   Serin, Guillaume ^d   Mirjolet, Jean Francois ^d   Bichat, Francis ^d   Rekdal, Øystein ^a,c  

^a LYTIX BIOPHARMA AS   (Norway)

^b UNIVERSITY OF BERGEN   (Norway)

^c UNIVERSITY OF TROMSØ   (Norway)

^d Oncodesign   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOCHROME P450; LTX 315; PEPTIDE; UNCLASSIFIED DRUG; CYTOCHROME P450 INHIBITOR; LTX-315; OLIGOPEPTIDE; PLASMA PROTEIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL LINE; CANCER RESISTANCE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENCY; DRUG SENSITIVITY; DRUG SYNTHESIS; ENZYME INHIBITION; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IN VITRO STUDY; LIVER CELL; NORMAL HUMAN; PLASMA PROTEIN BINDING; STRUCTURE ACTIVITY RELATION; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CHEMISTRY; DOG; DRUG DEVELOPMENT; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; DRUG STABILITY; HALF LIFE TIME; RAT; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; CELL LINE, TUMOR; CYTOCHROME P-450 ENZYME INHIBITORS; DOGS; DRUG DISCOVERY; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG STABILITY; HALF-LIFE; HUMANS; MICE, INBRED BALB C; OLIGOPEPTIDES; PEPTIDES; RATS;

EID: 84966292155     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/acs.jmedchem.5b02025     Document Type: Article

References (59)

1. Eggermont, A. M. M.; Kroemer, G.; Zitvogel, L. Immunotherapy and the concept of a clinical cure Eur. J. Cancer 2013, 49, 2965-2967 10.1016/j.ejca.2013.06.019
2. Chiocca, E. A.; Rabkin, S. D. Oncolytic viruses and their application to cancer immunotherapy Cancer Immunol. Res. 2014, 2, 295-300 10.1158/2326-6066.CIR-14-0015
3. Andtbacka, R. H. I.; Kaufman, H. L.; Collichio, F.; Amatruda, T.; Senzer, N.; Chesney, J.; Delman, K. A.; Spitler, L. E.; Puzanov, I.; Agarwala, S. S.; Milhem, M.; Cranmer, L.; Curti, B.; Lewis, K.; Ross, M.; Guthrie, T.; Linette, G. P.; Daniels, G. A.; Harrington, K.; Middleton, M. R.; Miller, W. H.; Zager, J. S.; Ye, Y.; Yao, B.; Li, A.; Doleman, S.; VanderWalde, A.; Gansert, J.; Coffin, R. Talimogene laherparepvec improves durable response rate in patients with advanced melanoma J. Clin. Oncol. 2015, 33, 2780-2788 10.1200/JCO.2014.58.3377
4. Al-Benna, S.; Shai, Y.; Jacobsen, F.; Steinstraesser, L. Oncolytic activities of host defense peptides Int. J. Mol. Sci. 2011, 12, 8027-8051 10.3390/ijms12118027
5. Kroemer, G.; Galluzzi, L.; Kepp, O.; Zitvogel, L. Immunogenic cell death in cancer therapy Annu. Rev. Immunol. 2013, 31, 51-72 10.1146/annurev-immunol-032712-100008
6. Berge, G.; Eliassen, L. T.; Camilio, K. A.; Bartnes, K.; Sveinbjørnsson, B.; Rekdal, ø. Therapeutic vaccination against a murine lymphoma by intratumoral injection of a cationic anticancer peptide Cancer Immunol. Immunother. 2010, 59, 1285-1294 10.1007/s00262-010-0857-6
7. Camilio, K. A.; Berge, G.; Ravuri, C. S.; Rekdal, ø.; Sveinbjørnsson, B. Complete regression and systemic protective immune responses obtained in B16 melanomas after treatment with LTX-315 Cancer Immunol. Immunother. 2014, 63, 601-613 10.1007/s00262-014-1540-0
8. Camilio, K. A.; Rekdal, ø.; Sveinbjörnsson, B. LTX-315 (Oncopore) A short synthetic anticancer peptide and novel immunotherapeutic agent OncoImmunology 2014, 3, e29181-e29183 10.4161/onci.29181
9. ClinicalTrials.gov NCT01058616.
10. ClinicalTrials.gov NCT01986426.
11. Tomita, M.; Bellamy, W.; Takase, M.; Yamauchi, K.; Wakabayashi, H.; Kawase, K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin J. Dairy Sci. 1991, 74, 4137-4142 10.3168/jds.S0022-0302(91)78608-6
12. Bellamy, W.; Takase, M.; Yamauchi, K.; Wakabayashi, H.; Kawase, K.; Tomita, M. Identification of the bactericidal domain of lactoferrin Biochim. Biophys. Acta, Protein Struct. Mol. Enzymol. 1992, 1121, 130-136 10.1016/0167-4838(92)90346-F
13. Rekdal, ø.; Andersen, J.; Vorland, L. H.; Svendsen, J. S. Construction and synthesis of lactoferricin derivatives with enhanced antibacterial activity J. Pept. Sci. 1999, 5, 32-45 10.1002/(SICI)1099-1387(199901)5:1<32::AID-PSC172>3.0.CO;2-9
14. Zasloff, M. Antimicrobial peptides of multicellular organisms Nature 2002, 415, 389-395 10.1038/415389a
15. Ganz, T. The role of antimicrobial peptides in innate immunity Integr. Comp. Biol. 2003, 43, 300-304 10.1093/icb/43.2.300
16. Yoo, Y.-C.; Watanabe, R.; Koike, Y.; Mitobe, M.; Shimazaki, K.-i.; Watanabe, S.; Azuma, I. Apoptosis in human leukemic cells induced by lactoferricin, a bovine milk protein-derived peptide: Involvement of reactive oxygen species Biochem. Biophys. Res. Commun. 1997, 237, 624-628 10.1006/bbrc.1997.7199
17. Eliassen, L. T.; Berge, G.; Sveinbjornsson, B.; Svendsen, J. S.; Vorland, L. H.; Rekdal, O. Evidence for a direct antitumor mechanism of action of bovine lactoferricin Anticancer Res. 2002, 22, 2703-2710
18. Mader, J. S.; Salsman, J.; Conrad, D. M.; Hoskin, D. W. Bovine lactoferricin selectively induces apoptosis in human leukemia and carcinoma cell lines Mol. Cancer Ther. 2005, 4, 612-624 10.1158/1535-7163.MCT-04-0077
19. Richardson, A.; de Antueno, R.; Duncan, R.; Hoskin, D. W. Intracellular delivery of bovine lactoferricin's antimicrobial core (RRWQWR) kills T-leukemia cells Biochem. Biophys. Res. Commun. 2009, 388, 736-741 10.1016/j.bbrc.2009.08.083
20. Hilchie, A. L.; Vale, R.; Zemlak, T. S.; Hoskin, D. W. Generation of a hematologic malignancy-selective membranolytic peptide from the antimicrobial core (RRWQWR) of bovine lactoferricin Exp. Mol. Pathol. 2013, 95, 192-198 10.1016/j.yexmp.2013.07.006
21. Hoskin, D. W.; Ramamoorthy, A. Studies on anticancer activities of antimicrobial peptides Biochim. Biophys. Acta, Biomembr. 2008, 1778, 357-375 10.1016/j.bbamem.2007.11.008
22. Riedl, S.; Zweytick, D.; Lohner, K. Membrane-active host defense peptides-Challenges and perspectives for the development of novel anticancer drugs Chem. Phys. Lipids 2011, 164, 766-781 10.1016/j.chemphyslip.2011.09.004
23. Gaspar, D.; Veiga, A. S.; Castanho, M. A. R. B. From antimicrobial to anticancer peptides. A review Front. Microbiol. 2013, 4, 1-16 10.3389/fmicb.2013.00294
24. Rapaport, D.; Shai, Y. Interaction of fluorescently labeled pardaxin and its analogues with lipid bilayers J. Biol. Chem. 1991, 266, 23769-23775
25. Ludtke, S. J.; He, K.; Heller, W. T.; Harroun, T. A.; Yang, L.; Huang, H. W. Membrane pores induced by magainin Biochemistry 1996, 35, 13723-13728 10.1021/bi9620621
26. Gazit, E.; Miller, I. R.; Biggin, P. C.; Sansom, M. S. P.; Shai, Y. Structure and orientation of the mammalian antibacterial peptide cecropin P1 within phospholipid membranes J. Mol. Biol. 1996, 258, 860-870 10.1006/jmbi.1996.0293
27. Miteva, M.; Andersson, M.; Karshikoff, A.; Otting, G. Molecular electroporation: a unifying concept for the description of membrane pore formation by antibacterial peptides, exemplified with NK-lysin FEBS Lett. 1999, 462, 155-158 10.1016/S0014-5793(99)01520-3
28. Pokorny, A.; Birkbeck, T. H.; Almeida, P. F. F. Mechanism and kinetics of δ-lysin interaction with phospholipid vesicles Biochemistry 2002, 41, 11044-11056 10.1021/bi020244r
29. Wimley, W. C. Describing the mechanism of antimicrobial peptide action with the interfacial activity model ACS Chem. Biol. 2010, 5, 905-917 10.1021/cb1001558
30. Wimley, W. C.; Hristova, K. Antimicrobial peptides: successes, challenges and unanswered questions J. Membr. Biol. 2011, 239, 27-34 10.1007/s00232-011-9343-0
31. Gee, M. L.; Burton, M.; Grevis-James, A.; Hossain, M. A.; McArthur, S.; Palombo, E. A.; Wade, J. D.; Clayton, A. H. A. Imaging the action of antimicrobial peptides on living bacterial cells Sci. Rep. 2013, 3, 1557 10.1038/srep01557
32. Brogden, K. A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria? Nat. Rev. Microbiol. 2005, 3, 238-250 10.1038/nrmicro1098
33. Utsugi, T.; Schroit, A. J.; Connor, J.; Bucana, C. D.; Fidler, I. J. Elevated expression of phosphatidylserine in the outer-membrane leaflet of human tumor-cells and recognition by activated human blood monocytes Cancer Res. 1991, 51, 3062-3066
34. Schibli, D. J.; Nguyen, L. T.; Kernaghan, S. D.; Rekdal, ø.; Vogel, H. J. Structure-function analysis of tritrpticin analogs: potential relationships between antimicrobial activities, model membrane interactions, and their micelle-bound NMR structures Biophys. J. 2006, 91, 4413-4426 10.1529/biophysj.106.085837
35. Rekdal, ø.; Haug, B. E.; Kalaaji, M.; Hunter, H. N.; Lindin, I.; Israelsson, I.; Solstad, T.; Yang, N.; Brandl, M.; Mantzilas, D.; Vogel, H. J. Relative spatial positions of tryptophan and cationic residues in helical membrane-active peptides determine their cytotoxicity J. Biol. Chem. 2012, 287, 233-244 10.1074/jbc.M111.279281
36. Riedl, S.; Rinner, B.; Schaider, H.; Lohner, K.; Zweytick, D. Killing of melanoma cells and their metastases by human lactoferricin derivatives requires interaction with the cancer marker phosphatidylserine BioMetals 2014, 27, 981-997 10.1007/s10534-014-9749-0
37. Riedl, S.; Leber, R.; Rinner, B.; Schaider, H.; Lohner, K.; Zweytick, D. Human lactoferricin derived di-peptides deploying loop structures induce apoptosis specifically in cancer cells through targeting membranous phosphatidylserine Biochim. Biophys. Acta, Biomembr. 2015, 1848, 2918-2931 10.1016/j.bbamem.2015.07.018
38. Lau, Q. Y.; Ng, F. M.; Cheong, J. W. D.; Yap, Y. Y. A.; Tan, Y. Y. F.; Jureen, R.; Hill, J.; Chia, C. S. B. Discovery of an ultra-short linear antibacterial tetrapeptide with anti-MRSA activity from a structure-activity relationship study Eur. J. Med. Chem. 2015, 105, 138-144 10.1016/j.ejmech.2015.10.015
39. 2,2-amino acid derivatives derived from antimicrobial peptides Biochim. Biophys. Acta, Biomembr. 2012, 1818, 2917-2925 10.1016/j.bbamem.2012.07.005
40. Hansen, T.; Alst, T.; Havelkova, M.; Strøm, M. B. Antimicrobial activity of small β-peptidomimetics based on the pharmacophore model of short cationic antimicrobial peptides J. Med. Chem. 2010, 53, 595-606 10.1021/jm901052r
41. 2,2-amino acid building block J. Pept. Sci. 2012, 18, 170-176 10.1002/psc.1434
42. 2,2-amino acid J. Pept. Sci. 2012, 18, 609-619 10.1002/psc.2441
43. Eliassen, L. T.; Haug, B. E.; Berge, G.; Rekdal, ø. Enhanced antitumour activity of 15-residue bovine lactoferricin derivatives containing bulky aromatic amino acids and lipophilic N-terminal modifications J. Pept. Sci. 2003, 9, 510-517 10.1002/psc.472
44. Haug, B. E.; Strøm, M. B.; Svendsen, J. S. M. The medicinal chemistry of short lactoferricin-based antibacterial peptides Curr. Med. Chem. 2007, 14, 1-18 10.2174/092986707779313435
45. Yang, N.; Rekdal, ø.; Stensen, W.; Svendsen, J. S. Enhanced antitumor activity and selectivity of lactoferrin-derived peptides J. Pept. Res. 2002, 60, 187-197 10.1034/j.1399-3011.2002.21008.x
46. Haug, B. E.; Skar, M. L.; Svendsen, J. S. Bulky aromatic amino acids increase the antibacterial activity of 15-residue bovine lactoferricin derivatives J. Pept. Sci. 2001, 7, 425-432 10.1002/psc.338
47. Isidro-Llobet, A.; Alvarez, M.; Albericio, F. Amino acid-protecting groups Chem. Rev. 2009, 109, 2455-2504 10.1021/cr800323s
48. Lan, Y.; Langlet-Bertin, B.; Abbate, V.; Vermeer, L. S.; Kong, X.; Sullivan, K. E.; Leborgne, C.; Scherman, D.; Hider, R. C.; Drake, A. F.; Bansal, S. S.; Kichler, A.; Mason, A. J. Incorporation of 2,3-diaminopropionic acid into linear cationic amphipathic peptides produces pH-sensitive vectors ChemBioChem 2010, 11, 1266-1272 10.1002/cbic.201000073
49. Yang, S.-T.; Shin, S. Y.; Lee, C. W.; Kim, Y.-C.; Hahm, K.-S.; Kim, J. I. Selective cytotoxicity following Arg-to-Lys substitution in tritrpticin adopting a unique amphipathic turn structure FEBS Lett. 2003, 540, 229-233 10.1016/S0014-5793(03)00266-7
50. Vogel, H. J.; Schibli, D. J.; Jing, W.; Lohmeier-Vogel, E. M.; Epand, R. F.; Epand, R. M. Towards a structure-function analysis of bovine lactoferricin and related tryptophan- and arginine-containing peptides Biochem. Cell Biol. 2002, 80, 49-63 10.1139/o01-213
51. Nguyen, L. T.; de Boer, L.; Zaat, S. A. J.; Vogel, H. J. Investigating the cationic side chains of the antimicrobial peptide tritrpticin: Hydrogen bonding properties govern its membrane-disruptive activities Biochim. Biophys. Acta, Biomembr. 2011, 1808, 2297-2303 10.1016/j.bbamem.2011.05.015
52. Powers, J. C.; Asgian, J. L.; Ekici, Ö. D.; James, K. E. Irreversible inhibitors of serine, cysteine, and threonine proteases Chem. Rev. 2002, 102, 4639-4750 10.1021/cr010182v
53. Eike, L.-M.; Yang, N.; Rekdal, ø.; Sveinbjørnsson, B. The oncolytic peptide LTX-315 induces cell death and DAMP release by mitochondria distortion in human melanoma cells Oncotarget 2015, 6, 34910-34923 10.18632/oncotarget.5308
54. Gennis, R. B. Biomembranes: Molecular Structure and Function; Springer-Verlag: New York, 1989.
55. Zhou, H.; Forveille, S.; Sauvat, A.; Sica, V.; Izzo, V.; Durand, S.; Müller, K.; Liu, P.; Zitvogel, L.; Rekdal, ø.; Kepp, O.; Kroemer, G. The oncolytic peptide LTX-315 kills cancer cells through Bax/Bak-regulated mitochondrial membrane permeabilization Oncotarget 2015, 6, 26599-26614 10.18632/oncotarget.5613
56. Spicer, J.; Awada, A.; Brunsvig, P. F.; Kristeleit, R.; Jøssang, D. E.; Saunders, A.; Olsen, W. M.; Nicolaisen, B.; Rekdal, ø.; Laruelle, M.; Marjuadi, F.; Vakili, J.; Aftimos, P.; Barthelemy, P.; Deva, S.; Jebsen, N. L.; Baurain, J.-F. Intra-tumoural treatment with LTX-315, an oncolytic peptide immunotherapy, in patients with advanced metastatic disease induces infiltration of CD8 effectors T-cells and regression in some injected tumors. Presented at the 18th European Cancer Congress, September 25-29, 2015, Vienna, Austria.
57. Mosmann, T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays J. Immunol. Methods 1983, 65, 55-63 10.1016/0022-1759(83)90303-4
58. Cory, A. H.; Owen, T. C.; Barltrop, J. A.; Cory, J. G. Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture Cancer Commun. 1991, 3, 207-212
59. Calculation of half-life using the Cornell University medical calculator: http://www-users.med.cornell.edu/∼spon/picu/calc/halfcalc.htm (accessed March 3, 2016).